Purpose: Limited data are available to describe the effectiveness of darbepoetin alfa (DA) in terms of hemoglobin (Hb) and transfusion outcomes when initiated at Hb r10 g/dL (the threshold specified in the summary of prescribing characteristics). We assessed DA, initiated according to current labeling (Hb r10 g/dL), in chemotherapy-induced anemia (CIA).
INTRODUCTION
Chemotherapy-induced anemia (CIA) is common in patients with cancer who are undergoing myelosuppressive chemotherapy. 1 In such patients, anemia has a detrimental effect on quality of life and can also negatively affect the patient's prognosis, increasing mortality rates by up to 65%. 2 In particular, anemia can often lead to the need for transfusions, which are associated with a range of issues, including the availability of suitable blood, the checks necessary to ensure the recipient's safety (eg, transfusion-transmitted diseases), the inconvenience to both patients and health care professionals, and the associated costs. 2 Treatments, such as erythropoiesis-stimulating agents (ESAs) that can increase hemoglobin (Hb) concentrations and thereby reduce the need for red blood cell transfusion 2 are therefore of great benefit to patients and health care systems. In 2008, the summary of product characteristics for the ESA darbepoetin alfa (DA) was updated, decreasing the Hb treatment initiation and discontinuation thresholds to r10 and 412 g/dL, respectively. 3 This was done as a result of data indicating that ESA treatment in patients with cancer was potentially associated with an increased risk of thromboembolic events and mortality, and similar changes were made by the Food and Drug Administration in the United States. 4 Because most clinical trials that investigated the effectiveness of DA in CIA were started before this update, limited data are available to describe the effectiveness of DA in terms of Hb and transfusion outcomes when initiated at Hb r10 g/dL. The landmark registration Phase III placebo-controlled trials of DA, for example, included patients when their Hb was o11 g/dL, and the dose of blinded study drug was withheld if a patient's Hb concentration increased to 415.0 g/dL (for men) or 414.0 g/dL (for women). 5, 6 After the patient's Hb concentration decreased to 13.0 g/dL, administration of the study drug was reinstated at 50% of the previous dose.
Several meta-analyses and systematic reviews have assessed the safety profile of ESAs in CIA, analyzed results in individual tumor types, and combined data for different ESAs. [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] These reviews found that ESA treatment can improve Hb concentrations and/or reduce the need for transfusion in patients with CIA. 10, [13] [14] [15] [16] Some reviews also suggest that ESA treatment can increase the rate of mortality when used inappropriately in patients with CIA, 7, 8, 12, 15 although others have found no increase in that rate of mortality. 9, 11, 13, 14, 16 These reviews have not, however, evaluated the effectiveness of DA in terms of Hb and transfusion outcomes in the subgroup of patients with a baseline Hb r10 g/dL.
We conducted a pooled analysis and meta-analysis that were based on data from Amgen-sponsored DA trials to assess the effectiveness of DA in CIA in patients who initiated DA at Hb r10 g/dL.
METHODS Objectives
The objective of this analysis was to summarize data on the effectiveness of DA when used according to the revised prescribing information and recommendations with an Hb treatment initiation threshold r10 g/dL for CIA. Effectiveness was assessed in terms of achievement of Hb targets (increase of Z1 g/dL and Z2 g/dL) and transfusion requirements.
Study Design
Data were sourced from a central database of Amgen-sponsored trials of DA in CIA. For comparative analyses, randomized controlled trials of DA in CIA that had at least 1 arm of a prespecified DA regimen versus control (placebo/best supportive care) were eligible for selection. Only data for DA arm(s) of permitted DA regimens and control data were extracted and were limited to patients who initiated DA at r10 g/L. For supportive analyses (DA-only analyses), randomized multiple-arm or prospective singlearm trials of DA in CIA that had at least 1 arm of a prespecified DA regimen were selected. Again, only data for DA arm(s) of permitted DA regimens were extracted and were limited to patients who initiated DA at r10 g/dL. Prespecified permitted DA regimens were 6.75 μg/kg (500 μg) every 3 weeks (Q3W), 2.25 μg/kg (150 μg) weekly (QW), 4.5 μg/kg (300 μg) Q3W, any 2-weekly regimen, and the QW 4.5 μg/kg (300 μg) front-loading dose regimen (ie, a high initial dose with the intention of subsequently reducing the dose and/or dose interval). Studies of 4-weekly DA, and all dose-finding studies, were excluded. In the DAonly analysis, data were analyzed separately for frontloading and non-front-loading DA regimens, because front-loading dosing is not licensed for DA. This was not done for the comparative analysis because the number of studies was too small.
Outcomes and Analyses
Outcomes included the percentage of patients with an Hb increase Z1 g/dL or Z2 g/dL, time to first Hb increase Z1 g/dL or Z2 g/dL, the percentage of patients who received a red blood cell transfusion from the start of week 5 (day 29), and time to first transfusion from day 29. Analyses were limited to data up to 12 weeks after the initiation of DA or control. Outcomes were also analyzed in subgroups of patients with Hb at treatment initiation o9 g/dL versus 9 to r10 g/dL.
For the comparative analysis, and separately for the DA-only analysis, study data were pooled to calculate crude and Kaplan-Meier percentages and time to each outcome of interest by treatment arm (DA or placebo for the comparative analysis; DA for the DA-only analysis). Kaplan-Meier plots were used to summarize time to each outcome of interest graphically. Crude percentages were calculated together with a Wilsons 95% CI. 17 The CI for Kaplan-Meier percentages were calculated by taking 1 minus the survivor function at the last noncensored time point (Greenwoods formula 18 ). For the comparative analysis only, meta-analysis techniques were used to calculate treatment effect for DA. An inverse-variance method was used (for both a random [DerSimonian-Laird] and fixed-effect model) on the basis of hazard ratios (HRs). I 2 statistics for heterogeneity were also calculated.
To confirm that exclusion of dose-finding studies in the original study design did not affect the overall findings, sensitivity analyses for the comparative analysis were conducted, including data from 2 DA dose-finding studies.
19,20

RESULTS
Studies Included
The database review identified 4 studies that met the inclusion and exclusion criteria for the comparative analysis (DA, n = 261; placebo, n = 273) ( Table I) . 5, 6, 21, 22 All 4 studies were Phase III randomized, double-blind, placebo-controlled trials. In addition, 2 placebo-controlled dose-finding studies were identified that included patients who initiated treatment at Hb r10 g/dL. These studies were excluded from the main analysis but were included in a sensitivity analysis. The database review for the DA-only analysis identified 15 relevant non-front-loading studies (n = 3768; Table II Baseline characteristics of the included patients are shown in Table III . Hematologic and lung cancers were the most common malignancies in the comparative analysis, and lung, gastrointestinal, breast, and hematologic cancers were most common in the DA-only analysis. Baseline age, disease stage, performance status, and Hb concentrations were similar for the DA and placebo groups of the comparative analysis and the population included in the DA-only analysis; average age across these groups ranged from 62.2 to 64.5 years, 475% of patients had disease stage III or higher (or extensive disease), and most patients had an Eastern Cooperative Oncology Group performance status of 0 or 1. Baseline Hb was 9.1 g/dL in the DA and placebo groups of the comparative analysis and 9.3 g/dL in the DA-only analysis.
Comparative Analysis
Mean Hb concentrations over time are shown in Figure 1 . On the basis of crude and Kaplan-Meier percentages, more patients who received DA achieved an increase in Hb of Z1 g/dL or Z2 g/dL versus placebo (Table IV) . Fixed-effect HRs for patients with an Hb increase of Z1 g/dL and Z2 g/dL for DA versus placebo were 2.07 (95% CI, 1.62-2.63) and 2.91 (95% CI, 2.09-4.06), respectively ( Figure 2) . Median time to a Z1 g/dL increase was 43 days (95% CI, 37-50 days) for DA and was not evaluable (NE) for placebo ( Figure 3A) . Median time to a Z2 g/dL increase was 78 days (95% CI, 71-NE days) for DA and was NE for placebo ( Figure 3B ). The crude and Kaplan-Meier percentages of DAtreated patients who achieved Hb increases Z1 g/dL and Z2 g/dL were similar in the subgroups of patients with baseline Hb o9 g/dL or Hb 9 to r10 g/dL (Table IV) . Fixed-effect HRs for an Hb increase of Z1 g/dL and Z2 g/dL for DA versus placebo were 1.61 (95% CI, 1.05-2.46) and 1.72 (95% CI, 1.03-2.85), respectively, for the Hb o9 g/dL subgroup, and 2.31 (95% CI, 1.72-3.11) and 3.70 (95% CI, 2.36-5.81) for the Hb 9 to r10 g/dL subgroup. In patients with baseline Hb o9 g/dL, median time to a Z1 g/dL increase was 49 days (95% CI, 43-52 days) for DA and 77 days (95% CI, 57-NE days) for placebo. In patients with baseline Hb 9 to r10 g/dL, median time to a Z1 g/dL increase was 43 days (95% CI, 29-50 days) for DA and NE for placebo.
On the basis of crude and Kaplan-Meier percentages, transfusions were more commonly required between the start of week 5 and end of week 12 in patients who received placebo than in patients who received DA (Table IV) . Fixed-effect HR for DA versus placebo was 0.58 (95% CI, 0.44-0.77) ( Figure 2C ). More patients with a baseline Hb o9 g/dL needed transfusions than patients with a baseline Hb 9 to r10 g/dL in both the DA and placebo arms (Table IV) . 
Sensitivity Analyses
The sensitivity analysis included 2 additional randomized, placebo-controlled, dose-finding studies, 19, 20 providing an overall total of 598 patients (DA, n = 313; placebo, n = 285). Inclusion of these 2 studies did not change the interpretation of the efficacy findings from the main comparative analysis.
DA-Only Analysis (non-front-loading data)
Mean Hb concentrations over time in the non-frontloading dose analysis are shown in Figure 1B . The crude and Kaplan-Meier percentages of patients who achieved a Z1 g/dL or Z2 g/dL increase in Hb were similar to the percentages seen for DA in the comparative analysis (Table IV) . Overall, the median time to an Hb increase Z1 g/dL was 43 days (95% CI, 43-43 days) ( Figure 4A) , and to an Hb increase of Z2 g/dL was 78 days (95% CI, 74-78 days) ( Figure 4B) . Results in patients with baseline Hb o9 g/dL or 9 to Z10 g/dL were similar to results for the r10 g/dL population in terms of crude and KaplanMeier percentages of patients who achieved a Z1 g/dL or Z2 g/dL increase in Hb (Table IV) and time to Hb increase 1 g/dL or 2 g/dL (data not shown).
The percentages of patients who required a transfusion on the basis of crude and Kaplan-Meier percentages were similar to those in the comparative analysis (Table IV) . Again, more patients with a baseline Hb o9 g/dL needed transfusions than patients with a baseline Hb 9 to r10 g/dL.
Results in the front-loading studies were similar to those in the non-front-loading studies (see online-only supplement).
DISCUSSION
This is the first patient-level meta-analysis, to our knowledge, to evaluate the efficacy, in terms of Hb response, of DA treatment when initiated according to the current product labeling in patients with CIA. The results of the comparative analysis confirm that DA is more effective than placebo at increasing serum Hb concentrations and at reducing the need for transfusion in patients with CIA when treatment is initiated at Hb r10 g/dL. Addition of 2 dose-finding studies did not change the findings of the main comparative analysis, and the results were consistent with the DAonly analyses, which included larger patient cohorts. The results of this analysis are consistent with previously published observational studies, post hoc analyses, chart reviews, and single-center studies of DA, which reported data on the efficacy of DA when initiated at Hb r10 g/dL.
34-41 For example, data from the CHOICE observational study in 1887 patients with solid tumors and CIA who received DA for 9 weeks found that 29% of patients who initiated treatment at Hb o9 g/dL and 20% of patients who initiated treatment at Hb 9 to o10 g/dL required a transfusion between the start of week 5 and end of treatment. 39 In a post hoc analysis of a Phase III study in patients with non-myeloid malignancies and CIA, Kaplan-Meier transfusion incidences with Q3W and QW DA were 36% and 41%, respectively, in patients who initiated treatment at Hb o10 g/dL. 40 Similarly, post hoc analysis of an earlier study in patients with lung cancer and CIA found that transfusion incidence with weekly DA was 31%. 40 The results of the present study are also consistent with studies of DA in patients with a broader range of baseline Hb concentrations, including those 410 g/dL. 6, 20, 22, 28, 30 Notably, the present analysis indicates similar efficacy outcomes regardless of whether DA was initiated at Hb concentrations o9 g/dL or 9 to r10 g/dL, although the need for transfusions was numerically higher in patients in the lower Hb category. This is consistent with an earlier exploratory analysis of data from a 15-week clinical trial by Canon et al 35 in which patients received DA 500 μg Q3W or 2.25 μg/kg QW. Results of that analysis suggested that baseline Hb o9 g/dL (n ¼ 126) was associated with worse outcomes than 9 to r10 g/dL (n ¼ 225) in terms of a Z1 g/dL increase in Hb within 14 days, and for achievement of Hb Z10 g/dL and need for transfusion. The researchers therefore recommended that treatment be initiated as soon as possible after Hb falls to 10 g/dL. 35 The strength of the present study is in the pooling of effectiveness data from multiple studies, particularly for the DA-only analyses; we recognize that a limited number of studies and patients were eligible for inclusion in the comparative analyses. Notably, the included studies were designed when DA was generally initiated at a higher Hb threshold, so only those data from the subset of patients who initiated Hb at r10 g/dL were extracted. In addition, this analysis of short-term (r26-week) studies focused on assessing the efficacy of DA specifically in patients whose treatment was initiated at the lower Hb threshold introduced by regulatory bodies in 2008. Analysis of longer-term end points in these patients, including key adverse events and survival, would be of great interest. Finally, it should be noted that non-Amgen trials of DA were not included.
CONCLUSIONS
The results of this pooled analysis suggest that DA is effective at rapidly increasing Hb concentrations and reducing the need for transfusions in patients with CIA when initiated after Hb falls to r10 g/dL, as per current product labeling.
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CONFLICTS OF INTEREST
Mean hemoglobin (Hb) levels over time are shown in Supplementary Figure 1 . In the analysis of frontloading DA doses, the crude and Kaplan-Meier percentages of patients achieving a Z1 g/dL or Z2 g/dL increase in Hb were generally similar, or slightly higher than the percentages seen for DA in the comparative and non-front-loading DA-only analyses (Supplementary Table III Figure 2a) ; the median (95% CI) time to an Hb increase Z2 g/dL was 64 (57-71) days (Supplementary Figure 2b) . Results in patients with baseline Hb o9 g/dL or 9-Z10 g/dL were similar to those for the r10 g/dL population in terms of crude and Kaplan-Meier percentages of patients achieving a Z1 g/dL or Z2 g/dL increase in Hb (Supplementary Table III) , and time to Hb increase 1 g/dL or 2 g/dL (data not shown).
The percentages of patients requiring a transfusion based on crude and Kaplan-Meier percentages were similar to those in the comparative and non-frontloading DA only analyses (Supplementary Table III) . Again, more patients with a baseline Hb o9 g/dL needed transfusions than those with a baseline Hb 9-r10 g/dL. Figure S1 . Mean hemoglobin levels during the first 12 weeks of treatment in the darbepoetin-only frontloading analyses. Error bars represent 95% confidence intervals. 835  812  772  704  630  549  472  411  361  323  280  225  0  0  3  30  79  135  203  262  306  343  366  386  412  430 Note: Hemoglobin measurements within 28 days after a teansfusion are execluded from the analysis median a b Figure S2 . Kaplan-Meier curve for time to a) increase in hemoglobin of Z1 g/dL during the first 12 weeks of treatment, and b) increase in hemoglobin of Z2 g/dL during the first 12 weeks of treatment in patients receiving darbepoetin alfa (darbepoetin-only non-front-loading analysis).
